You have 9 free searches left this month | for more free features.

nab-paclitaxel

Showing 1 - 25 of 3,408

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Breast Cancer Trial (RO7247669, Pembrolizumab, Nab-Paclitaxel)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
May 2, 2023

Metastatic Pancreatic Cancer, Adenocarcinoma of the Pancreas Trial in Weiden (nab-paclitaxel and gemcitabine, gemcitabine mono

Completed
  • Metastatic Pancreatic Cancer
  • Adenocarcinoma of the Pancreas
  • nab-paclitaxel and gemcitabine
  • gemcitabine mono and nab-paclitaxel and gemcitabine
  • Weiden, Germany
    Kliniken Nordoberpfalz AG, Klinikum Weiden
Nov 21, 2022

TNBC Trial in Shanghai (PM8002, nab-paclitaxel)

Recruiting
  • TNBC
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Jun 25, 2023

Pancreatic Cancer Trial (TTX-030, nab-paclitaxel and gemcitabine, TTX-030, budigalimab, nab-paclitaxel and gemcitabine,

Not yet recruiting
  • Pancreatic Cancer
  • TTX-030, nab-paclitaxel and gemcitabine
  • +2 more
  • (no location specified)
Nov 3, 2023

Pancreatic Adenocarcinoma Metastatic Trial in Nanjing (Penpulimab, Anlotinib, Nab paclitaxel)

Recruiting
  • Pancreatic Adenocarcinoma Metastatic
  • Nanjing, Jiangsu, China
    The Affiliated Nanjing Drum Tower Hospital of Nanjing University
Sep 18, 2023

Advanced Biliary Tract Cancer Trial (anlotinib+TQB2450+nab-paclitaxel+cisplatin)

Not yet recruiting
  • Advanced Biliary Tract Cancer
  • (no location specified)
Apr 2, 2023

Metastatic Pancreatic Cancer Trial in Washington (Gemcitabine, Nab paclitaxel, Proglumide Dose level 1)

Not yet recruiting
  • Metastatic Pancreatic Cancer
  • Washington, District of Columbia
    Lombardi Comprehensive Cancer Center, Georgetown University
Aug 24, 2023

Gastric Cancer, GastroEsophageal Cancer Trial in Wuhan (Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor), Albumin-bound

Active, not recruiting
  • Gastric Cancer
  • GastroEsophageal Cancer
  • Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor)
  • Albumin-bound Paclitaxel
  • Wuhan, Hubei, China
    Tongji hospital of Tongji Medical College, Huazhong University o
Jan 21, 2023

Triple-Negative Breast Cancer Trial in Shanghai (Camrelizumab plus Famitinib with/without nab-Palitaxel)

Not yet recruiting
  • Triple-Negative Breast Cancer
  • Camrelizumab plus Famitinib with/without nab-Palitaxel
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center Shanghai, China, 200032
Jan 2, 2023

Pancreatic Cancer Trial in Meldola, Ravenna (Losartan, Gemcitabine, Nab paclitaxel)

Not yet recruiting
  • Pancreatic Cancer
  • Meldola, Forlì, Italy
  • +1 more
May 12, 2023

Breast Tumors Trial in Hangzhou (Sindilimab, Nab-paclitaxel, Lenvatinib)

Not yet recruiting
  • Breast Neoplasms
  • Hangzhou, Zhejiang, China
    ZhejiangCH
Nov 17, 2023

HR+/HER2- Breast Cancer Trial (Tucidinostat, nab-paclitaxel)

Not yet recruiting
  • HR+/HER2- Breast Cancer
  • (no location specified)
Nov 21, 2022

Metastatic Pancreatic Adenocarcinoma Trial in Shanghai (Ascorbate, Nab paclitaxel, Gemcitabine)

Recruiting
  • Metastatic Pancreatic Adenocarcinoma
  • Shanghai, Shanghai, China
    Shanghai Cancer Center
Aug 29, 2023

Her-2 Negative Breast Cancer, HRR Gene Mutation Trial in Guangzhou (Camrelizumab, Fluzoparib, Nab-paclitaxel)

Recruiting
  • Her-2 Negative Breast Cancer
  • HRR Gene Mutation
  • Guangzhou, Guangdong, China
    First Affiliated Hospital, Sun Yat-Sen University
Mar 7, 2023

Metastatic Pancreatic Cancer Trial in Washington (Gemcitabine, Nab paclitaxel, Proglumide Dose level 1)

Not yet recruiting
  • Metastatic Pancreatic Cancer
  • Washington, District of Columbia
    Lombardi Comprehensive Cancer Center, Georgetown University
Apr 11, 2023

Pancreatic Cancer Trial in Boston, Philadelphia (Gemcitabine, Nab-paclitaxel, Paricalcitol)

Active, not recruiting
  • Pancreatic Cancer
  • Boston, Massachusetts
  • +1 more
Jan 9, 2023

Resectable Pancreatic Cancer, Ductal Adenocarcinoma of the Pancreas Trial in Ulm (perioperative nab-paclitaxel/gemcitabine,

Completed
  • Resectable Pancreatic Cancer
  • Ductal Adenocarcinoma of the Pancreas
  • perioperative nab-paclitaxel/gemcitabine
  • adjuvant nab-paclitaxel/gemcitabine
  • Ulm, Germany
    University of Ulm, Dept. of Internal Medicine I
Nov 21, 2022

Uterine Cervical Tumors, Cancer of Cervix, Cervical Cancer Trial (Cadonilimab, Nab paclitaxel)

Not yet recruiting
  • Uterine Cervical Neoplasms
  • +5 more
  • (no location specified)
Apr 9, 2023

Gastric Cancer, Peritoneal Metastases, Ascites, Malignant Trial in Hangzhou (Sintilimab in Combination With S-1/oxaliplatin With

Recruiting
  • Gastric Cancer
  • +2 more
  • Sintilimab in Combination With S-1/oxaliplatin With nab-paclitaxel intraperitoneal infusion
  • Blood samples, tumor biopsy specimens, ascites, and feces samples will be collected
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Sep 18, 2023

Bladder Cancer Trial in Tianjin (Cadonilimab)

Recruiting
  • Bladder Cancer
  • Tianjin, Tianjin, China
    Tianjin Medical University Second Hospital
Aug 23, 2023

Breast Cancer Trial in Haidian (nab-paclitaxel regimen1, nab-paclitaxel regimen2)

Active, not recruiting
  • Breast Cancer
  • nab-paclitaxel regimen1
  • nab-paclitaxel regimen2
  • Haidian, Beijing, China
    BeijingCancerH
Oct 11, 2022

Pancreatic Cancer Trial in New York (Canakinumab, Tislelizumab, Nab-Paclitaxel)

Recruiting
  • Pancreatic Cancer
  • New York, New York
  • +2 more
Aug 2, 2023

Solid Tumors Trial in United States (CORT125134 with nab-paclitaxel)

Completed
  • Solid Tumors
  • Relacorilant with nab-paclitaxel
  • Scottsdale, Arizona
  • +3 more
Nov 9, 2022

Pancreatic Cancer, Stage IB, Pancreatic Cancer, Stage IIA, Pancreatic Cancer, Stage IIB Trial in Shanghai (sintilimab,

Not yet recruiting
  • Pancreatic Cancer, Stage IB
  • +3 more
  • Shanghai, Shanghai, China
    Zhongshan Hospital
Jan 4, 2023

Muscle Invasive Bladder Cancer, Urothelial Carcinoma Trial in Tianjin (Tislelizumab, Nab paclitaxel)

Active, not recruiting
  • Muscle Invasive Bladder Cancer
  • Urothelial Carcinoma
  • Tianjin, Tianjin, China
    Tianjin Medical University Second Hospital
Nov 23, 2022